Euro vs US Dollar

Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.

Registrieren

ADAG Adagene Inc

1,42

0,02 (1,43%)

Vor Marktöffnung

Zuletzt aktualisiert: 10:45:20

Verzögert um 15 Minuten

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors

Adagene (NASDAQ:ADAG)
Historical Stock Chart
Von Mär 2025 bis Apr 2025

Click Here for more Adagene Charts.

Adagene (NASDAQ:ADAG)
Historical Stock Chart
Von Apr 2024 bis Apr 2025

Click Here for more Adagene Charts.

News Adagene Inc

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
Montag 24 März 2025 (2 Wochen vor) • Edgar (US Regulatory)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Montag 24 März 2025 (2 Wochen vor) • Edgar (US Regulatory)

Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
Mittwoch 19 Februar 2025 (2 Monate vor) • Edgar (US Regulatory)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Montag 27 Januar 2025 (2 Monate vor) • Edgar (US Regulatory)

Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend]
Donnerstag 7 November 2024 (5 Monate vor) • Edgar (US Regulatory)

Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend]
Donnerstag 7 November 2024 (5 Monate vor) • Edgar (US Regulatory)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Donnerstag 7 November 2024 (5 Monate vor) • Edgar (US Regulatory)

Adagene Presents Two Posters with New Insights on Increased Therapeutic Index for Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) and Data Reinforcing Clinical Safety and Efficacy for ADG126 as Monotherapy and in Combination with Anti-PD-1 Therapy at Soc
Donnerstag 7 November 2024 (5 Monate vor) • GlobeNewswire Inc.

Adagene Announces Upcoming Poster Presentations on Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) at Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
Mittwoch 9 Oktober 2024 (6 Monate vor) • GlobeNewswire Inc.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Montag 16 September 2024 (7 Monate vor) • Edgar (US Regulatory)

Adagene Presents Results at ESMO Congress that Show Best-in-Class Therapeutic Potential for Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) in Combination with KEYTRUDA® (Pembrolizumab) in Advanced/Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC
Montag 16 September 2024 (7 Monate vor) • GlobeNewswire Inc.

Adagene to Participate in Investor Conferences in September
Donnerstag 29 August 2024 (7 Monate vor) • GlobeNewswire Inc.

Weitere Adagene Inc News-Artikel

Rivian Automotive

Amundi Index Sol Amundi ...

Acadia Pharmaceuticals

Bayerische Motoren Werke

Direxion Daily AAPL Bull...

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen